pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 24·1 min read
save

Daiichi Sankyo delays release of annual results, shares fall

Apr 24, 2026·read at Endpoints ↗Negative

Daiichi Sankyo announced it will postpone the reporting of its annual results, saying more time is needed to finalize the numbers.

The company had planned to unveil the financials for its fiscal year that ended recently, but the schedule has been pushed back.

The news triggered a dip in Daiichi Sankyo's stock price in early trading.

No further details on the financial performance were provided in the brief announcement.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Daiichi Sankyo postpones annual results, stock dips”

read at Endpoints ↗
81 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
DAIICHI SANKYO4

related stories

  • Aug 28Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMOEndpoints
  • Aug 28Genentech doubles down on ADC-resistant cancers with $1B DualityBio pactFierce Biotech
  • Aug 27Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushFierce Biotech
  • Aug 26Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ ZiiheraBioSpace
  • Aug 10RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 winEndpoints